GlassScriptPhysician profile
Michael Durante
NPI 1801545322
$4,045.63
in general payments reported to CMS, 2019-2025
22 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $140 · 2024: $1,399 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.42 |
| Education | $404.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,091.65 | 2024-2025 | Carvykti, Darzalex, Rybrevant |
| Astellas Pharma US INC | $360.96 | 2025 | |
| Daiichi Sankyo INC. | $355.51 | 2024-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $226.76 | 2025 | Ojjaara, Jemperli |
| Pfizer INC. | $213.26 | 2024-2025 | |
| Genzyme Corporation | $206.14 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.68 | 2024-2025 | Libtayo |
| Beone Medicines USA, INC. | $150.00 | 2025 | Tevimbra |
| Legend Biotech USA INC. | $147.26 | 2025 | Carvykti |
| Celgene Corporation | $139.45 | 2025 | Reblozyl |
| Janssen Scientific Affairs, LLC | $136.96 | 2025 | Akeega, Balversa, Erleada |
| Incyte Corporation | $128.83 | 2024 | |
| Jazz Pharmaceuticals INC. | $124.51 | 2025 | |
| Amgen INC. | $123.71 | 2025 | Blincyto |
| Recordati_rare_diseases_inc. | $123.21 | 2025 | Sylvant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $121.82 | 2024 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $71.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $65.29 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $22.93 | 2025 | Opdivo |
| Beigene USA, INC. | $21.14 | 2025 | Brukinsa |
| Geron Corporation | $19.64 | 2025 | Rytelo |
| Gilead Sciences, INC. | $14.12 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Durante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.